Clinical Trial Update: Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the optimal interval between cycles of Lutathera (177Lu-DOTATATE) peptide receptor radionuclide therapy in SSTR2-positive neuroe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Neuroendocrine Tumors | Phase 2 | Status: ACTIVE_NOT_RECRUITING